Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M635Revenue $M15.0Net Margin (%)-216.0Altman Z-Score1.9
Enterprise Value $M403EPS $-1.8Operating Margin %-296.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-216.0Higher ROA y-yY
Price/Book0.910-y EBITDA Growth Rate %--Quick Ratio9.6Cash flow > EarningsN
Price/Sales18.75-y EBITDA Growth Rate %8.1Current Ratio9.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-12.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-16.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M54.2ROIC % (ttm)-79.5Gross Margin Increase y-yN

Gurus Latest Trades with TKMR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TKMRFirst Eagle Investment 2013-06-30 Sold Out $4.28 - $5.05
($4.74)
$ 11.71147%Sold Out0
TKMRFirst Eagle Investment 2013-03-31 Buy $4.35 - $5.44
($4.73)
$ 11.71148%New holding25,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TKMR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


TKMR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lutwyche, PeterDirector or Senior Officer of Insider or Subsidiar 2014-12-01Sell18,000$18.43-34.78 view
Phillips, Peggy VanSiceDirector 2014-06-19Buy5,000$13.6-11.62 view
Phillips, Peggy VanSiceDirector 2014-06-18Buy5,000$13.6-11.62 view
Jewell, DonaldDirector 2014-06-16Buy2,450$14.14-14.99 view
Jewell, DonaldDirector 2013-08-06Buy400$6.197.05 view
Jewell, DonaldDirector 2013-08-06Buy400$6.0997.37 view
Jewell, DonaldDirector 2013-08-06Buy500$6.197.05 view
Jewell, DonaldDirector 2013-08-06Buy300$6.0997.37 view
Murray, Mark JosephSenior Officer 2013-04-16Buy5,000$4.6161.3 view
Jewell, DonaldDirector 2013-03-12Buy1,200$4.44170.72 view

Quarterly/Annual Reports about TKMR:

News about TKMR:

Articles On GuruFocus.com
watching Jun 21 2015 
watching Jun 21 2015 
Gurus Purchase Tekmira Pharmaceuticals in Q1 Jun 19 2015 
John Griffin's New Buys During Q1 2015 May 29 2015 
Tekmira Pharmaceuticals Gets Mixed Ratings After Ebola Drug Updates Nov 11 2014 
Ebola: Is The Cure Out There? Oct 14 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

More From Other Websites
Can Hepatitis B Be A Blockbuster Bug? Jul 01 2015
5 Biotech Stocks On Deck With The FDA Jun 30 2015
Edited Transcript of TKMR presentation 24-Jun-15 6:00pm GMT Jun 30 2015
Sierra Leone's Freetown Set Back In Ebola Eradication Jun 23 2015
Researchers Put Brakes on Study of Tekmira Ebola Drug in West Africa Jun 19 2015
Tekmira says Ebola drug unlikely to work in study Jun 19 2015
Tekmira says Ebola drug unlikely to work in study Jun 19 2015
Tekmira stops adding patients in African study of Ebola drug Jun 19 2015
Tekmira stops adding patients in African study of Ebola drug Jun 19 2015
Tekmira: With Its Ebola Drug Gone, Is It Worth the Risk? Jun 19 2015
Tekmira halts enrollment on Ebola tests; shares fall Jun 19 2015
Tekmira Tumbles On Ominous Signs For Ebola Drug Jun 19 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 19 2015
Tekmira Provides Update on TKM-Ebola-Guinea Jun 19 2015
Tekmira to Present at JMP Securities Life Sciences Conference Jun 18 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 18 2015
Tekmira to Present at JMP Securities Life Sciences Conference Jun 18 2015
Tekmira Pharma downgraded by Maxim Group Jun 15 2015
Dementia drug developer Axovant climbs after $315M IPO Jun 11 2015
Dementia drug developer Axovant climbs after $315M IPO Jun 11 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK